Compare Palo Alto Networks Inc (PANW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Palo Alto Networks Inc trades at $336.21 (market cap $274.64B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Palo Alto Networks Inc is far larger — about 2× Vertex Pharmaceuticals Incorporated's market cap. Which is the better fit depends on your goals.
| PANW | VRTX | |
|---|---|---|
Market Cap | $274.64B | $134.06B |
Sector | Technology | Health |
52-Week High | $396.00 | $557.96 |
52-Week Low | $141.67 | $376.62 |
Enterprise Value | $273.60B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $336.98, up 1.12% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $9.22B in FY2025, with strong gross margins of 71.94%, but valuation ratios are elevated (P/E 293.03, P/S 23.39). The company is set to join the S&P 500, reflecting its leadership in AI cybersecurity, though rising costs and premium pricing pose challenges.
Outlook remains positive due to AI-driven security demand and platformization strategy, but high valuation and competitive pressures warrant caution. Analyst consensus is bullish with a $410.48 price target, yet near-term volatility may persist as the stock digests recent gains and faces execution risks in a dynamic cybersecurity landscape.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
